CN1513515A - Medicine for treating dermatosis and its preparation method - Google Patents
Medicine for treating dermatosis and its preparation method Download PDFInfo
- Publication number
- CN1513515A CN1513515A CNA031353622A CN03135362A CN1513515A CN 1513515 A CN1513515 A CN 1513515A CN A031353622 A CNA031353622 A CN A031353622A CN 03135362 A CN03135362 A CN 03135362A CN 1513515 A CN1513515 A CN 1513515A
- Authority
- CN
- China
- Prior art keywords
- medicine
- tripterygium hypoglaucum
- treatment
- mixture
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating dermatopathy, especially the photodermatopathy and aseptic pustulosis, is prepared from 9 Chinese-medicinal materials including scutellaria root, dittany bark, red sage root, corydalis tuber, etc. Its advantages are high curative effect and low poison.
Description
Technical field
The present invention relates to the dermopathic medicine of a kind of treatment, is the Chinese patent medicine of feedstock production with the Chinese herbal medicine specifically, the invention still further relates to the preparation method of this medicine.
Background technology
(triterygium hypoglaucum hutch THH) is a kind of medicinal plants of abounding with in Yunnan Province, aboundresources, low price to Tripterygium hypoglaucum.Many medical experts carried out further investigation to this medicine, and clear and definite THH has antiinflammatory, immunomodulating, antitumor, antivirus action, but also has more side effect, as tangible symptom of digestive tract, Liver and kidney toxicity, reproductive system influence etc.
Since the sixties in 20th century, the elder brother cures old experts such as the old expert of the attached First Academy easypro ripples, Shu Shangyi and Wang Zhengwen this medicine was carried out further investigation, find that THH has better curative effect to rheumatoid arthritis, lupus erythematosus, behcets disease etc., effective percentage reaches more than 70%, and its achievement obtains first Award for Science and Technology, Yunnan Province.
The elder brother cures the attached First Academy department of dermatologry Tripterygium hypoglaucum is furtherd investigate again, Tripterygium hypoglaucum is used for clinical, treats multiple and the relevant dermatosis of immunity, and is good especially to light dermatoses and aseptic impetigo curative effect.1997 " Tripterygium hypoglaucum is to the researchs of aseptic pustule pro-inflammatory cytokine level affects " obtain the applied basic research of Yunnan Province Science and Technology Department and subsidize (97C031Q), go through research in 3 years, summed up the Tripterygium hypoglaucum treatment impetiginous experience of aseptic and illustrated its mechanism of action, its achievement obtained Yunnan Province's scientific and technological progress third prize in 2002.Its result shows that THH treatment aseptic impetigo effective percentage reaches 96.8%, for the intractable aseptic impetigo in the world provides a kind of effective treatment means.Though THH has antiinflammatory, immunoregulation effect preferably, stronger GI irritation reaction is arranged, certain Liver and kidney toxicity is arranged, spanomenorrhea, amenorrhea are arranged and people's sperm is had side effect such as teratogenesis, influence its extensive use clinically.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, thus provide a kind of not only to the treatment dermatosis have curative effect preferably, but also can reduce Tripterygium hypoglaucum toxicity, strengthen the treating skin disease agent that its antiinflammatory, immunoregulation effect have better clinical use value.
Another object of the present invention provides the preparation method of this treating skin disease agent.
Solution of the present invention be according to the traditional Chinese medical science " main and auxiliary, help, make " theory and modern Chinese medicine theory on the basis of THH, be aided with nine flavor medicines such as Radix Scutellariae, Radix Glycyrrhizae and form compound preparations.Can treat the many disease relevant with immunity, have curative effect preferably to treating 12 kinds of dermatosiss, wherein good especially to light dermatoses and aseptic impetigo curative effect, the effective percentage pro-is more than 82%.Result of study shows: the compound recipe Tripterygium hypoglaucum is lower than Tripterygium hypoglaucum list agent toxicity, and bigger safety is arranged.Its mechanism of action can be by being the secretion that suppresses IFN-γ, thereby the expression of downward modulation ICAM-1, suppress the lymphocytic activation of T and reduce the generation of T lymphocyte chemotactic and inflammatory factor, reduce the infiltration of local single nucleus and play antiinflammatory, immunoregulatory effect.The compound recipe Tripterygium hypoglaucum has stronger anti-mice photoallergy effect than the agent of Tripterygium hypoglaucum list.
Medicine of the present invention is made by following component: (consumption is a weight portion)
Tripterygium hypoglaucum 15～30 Herba Artemisiae Annuaes 6～12 Radix Scutellariaes 3～9 Cortex Dictamnis 4.5～9
Radix Salviae Miltiorrhizae 9～15 Rhizoma Corydalis 3～9 Rhizoma Pinelliae Preparata 3～9 Semen Cuscutae 6～12 Radix Glycyrrhizaes 1.5～9
Formula optimization weight (part) ratio range of preparation medicine of the present invention is:
Tripterygium hypoglaucum 12～25 Herba Artemisiae Annuaes 8～10 Radix Scutellariaes 5～7 Cortex Dictamnis 5.5～7
Radix Salviae Miltiorrhizae 10～12 Rhizoma Corydalis 5～7 Rhizoma Pinelliae Preparata 5～7 Semen Cuscutae 8～10 Radix Glycyrrhizaes 3.5～7
Above-mentioned each component is made medicine production method of the present invention is:
(1) after being mixed in proportion, above-mentioned medicine raw material is crushed to coarse granule;
(2) soaked 10～12 hours;
(3) 60 ℃, slow fire boiling extracted secondary about 30 minutes in the multi-functional extractor;
(4) get volatile oil and filtrate, merge secondary filtrate;
(5) filtrate is concentrated;
(6) add volatile oil, antiseptic, correctives;
(7) quality control, packing, sterilization, dermopathic mixture can obtain medical treatment.
Medicine of the present invention also can be made into granule or capsule, and its preparation method is:
(1) identical to (5) step with above-mentioned mixture;
(6) concentrate the back spray drying, get extract powder;
(7) add volatile oil, sucrose dextrin, granulate drying;
(8) granulate, total mixing, the granule packing, packing, quality examination gets finished product.
The characteristics of medicine of the present invention are to be principal agent with the Tripterygium hypoglaucum; be aided with clearing heat and expelling damp, eliminating inflammation and expelling toxin, antianaphylactic Herba Artemisiae Annuae, Radix Scutellariae, Cortex Dictamni enhancing antiinflammatory, immunoregulation effect; assistant with the Rhizoma Corydalis of calmness, pain relieving, gastric acid inhibitory secretion, protection gastric mucosa, Rhizoma Pinelliae Preparata to alleviate its gastrointestinal reaction; assistant reduces its toxic and side effects to reproductive system with the Semen Cuscutae of the kidney invigorating and essence nourishing; with the Radix Glycyrrhizae is messenger drug; QI invigorating and in, concoct all medicines and formed compound recipe Tripterygium hypoglaucum mixture.
To THH from single agent to compound preparation, all done series of studies to experiment from clinical, its result shows medicine of the present invention (compound recipe Tripterygium hypoglaucum), good especially with light dermatoses and aseptic impetigo curative effect, its effect is better than the agent of Tripterygium hypoglaucum list, and sophisticated mixture preparation technology has been arranged, established solid foundation for developing compound recipe Tripterygium hypoglaucum granule from now on.
Below show that with clinical observation medicine of the present invention is to the treating for skin disease effect:
The clinical observation of medicine of the present invention:
The dermopathic evaluation of clinical curative effect of kind surplus the Drug therapy 10 of the present invention: oral with medicine of the present invention (mixture), every day potion, 1/2 of the above-mentioned dosage of children's dress below 2/3,10 years old of the above-mentioned dosage of 10-14 year children's dress, continued treatment 1-3 month.Curative effect see the following form [example/(%)]:
61 24 ( 39.34 ) 18 ( 29.50 ) 9 ( 14.75 ) 10 ( 16.39 ) 68.85 83.61 50 9 22 10 9 62.00 82.00 ( 18.00 ) ( 44.00 ) ( 20.00 ) ( 18.00 ) 22 2 ( 9.09 ) 9 ( 40.91 ) 8 ( 36.36 ) 3 ( 13.64 ) 50.00 86.36 14 3 ( 21.34 ) 6 ( 42.86 ) 3 ( 21.42 ) 2 ( 14.29 ) 64.29 87.51 32 12 ( 37.50 ) 14 ( 43.75 ) 5 ( 15.62 ) 1 ( 3.31 ) 81.52 96.87 36 12 ( 33.33 ) 14 ( 38.89 ) 8 ( 22.22 ) 2 ( 5.56 ) 72.22 94.44 32 6 ( 18.75 ) 12 ( 37.50 ) 10 ( 31.25 ) 4 ( 12.50 ) 56.25 87.50 35 10 ( 28.57 ) 15 ( 42.86 ) 7 ( 20.00 ) 3 ( 8.57 ) 71.43 91.43 14 2 4 4 4 42.85 71.43
(14.29) (28.57) (28.57) (28.57) psoriasis 38 8 (21.05) 14 (36.84) 8 (21.05) 8 (21.05) 57.89 78.94
Medicine of the present invention and Tripterygium hypoglaucum water are carried the toxicity test with alcohol extract
(1) trial test is carried out in the water anxious poison test of carrying THH earlier, records Dn (LD
0) be 45g/kg, Dm (LD
100) be 119g/kg, during this period, survey LD
50, above-mentioned mice is divided into 6 groups at random, 10 every group, be respectively 5 dosage group: 47.52g/kg that water is carried THH, 59.40g/kg 74.25g/kg, 92.81g/kg, 116.02g/kg, the group spacing is 0.8, one normal saline matched group.Begin to have the movable minimizing of mice behind the gastric infusion 32min, drowsiness, weak, bradykinesia is breathed and is weakened gradually; Lip, limb, tail cyanosis appear behind the 56min, dyspnea; Begin to have dead mouse behind the 72min, tic of the limbs occurs before the part dead mouse.Most of mices are dead in 24h, and the death time is no more than 72h at the latest.Perusal each internal organs that become celestial are not seen change.Record median lethal dose(LD 50) (LD with the Bliss method
50) be 78.02g/kg, its credible 67.51～90.17g/kg that is limited to of 95% sees table 1 for details.None example of matched group is dead.
Table 1 water is carried the acute toxicity test (LD that THH once irritates stomach
50) (Bliss method)
Dosage log10 dose number of animals dead animal is counted the LD of mortality rate probit
50And 95% can
(g/kg) (X) (%) (Y) letter limit (g/kg) of (only) (only)
47.52 1.6769 10 1 10％(0.1) 0.8694
59.40 1.7738 10 2 20％(0.2) 2.2728 78.02
74.25 1.8707 10 5 50％(0.5) 4.4598 (67.51～90.17)
92.81 1.9676 10 6 60％(0.6) 6.830
116.02 2.0645 10 9 90％(0.9) 8.6177
(2) the anxious poison test of alcohol extraction THH is the same, carries out trial test earlier, records Dn (LD
0) be 20.8g/kg, Dm (LD
100) be 58.4g/kg, during this period, survey LD
50, above-mentioned mice is divided into 6 groups at random, 10 every group, be respectively 5 dosage group gastric infusions of alcohol extraction THH, see table 2 for details.None example of matched group is dead.
Table 2 alcohol extraction THH once irritates the anxious poison (LD of stomach
50) (Bliss method)
Dosage log10 dose number of animals dead animal is counted the LD of mortality rate probit
50And 95% can
(g/kg) (X) (%) (Y) letter limit (g/kg) of (only) (only)
21.65 1.3355 10 1 10％(0.1) 1.0257
27.06 1.4323 10 3 30％(0.3) 2.4265 35.57
33.83 1.5293 10 4 40％(0.4) 4.4911 (30.5～41.46)
42.29 1.6262 10 6 60％(0.6) 6.7066
52.86 1.7231 10 9 90％(0.9) 8.4402
(3) maximum tolerated dose of compound recipe THH (medicine of the present invention): trial test, with compound recipe THH Cmax 5.49g/ml, maximum volume 0.4ml/10g irritates stomach once, observes a week, does not see dead mouse, then transforms mtd test into.Get 40 of above-mentioned mices, be divided into 2 groups at random: (1) compound recipe THH group; (2) blank group.Every group 20, mice fasting 6h before the test, with compound recipe THH Cmax 5.49gml, 0.4ml/10g irritates stomach 2 times, interval 4h, the blank group is given the normal saline (0.4ml/10g) of equivalent.Observed for 2 weeks, the performance of record mice, food ration, feces and death etc., not dead mice performed an autopsy on sb after 2 weeks.Press 20 mices of compound recipe THH439.20g/kg (crude drug amount) administration, the same day and after see that mice activity, behavior are no abnormal, food ration, body weight and blank group no significant difference do not have dead in 2 weeks and other abnormal conditions generation.2 groups of mices were put to death simultaneously and perform an autopsy on sb in the 14th day, and main organs (heart, lung, liver,kidney,spleen, stomach) is not seen difference through naked eyes.Therefore, the maximum tolerated dose that compound recipe water is proposed the administration of THH its mouse oral is 439.20g/kg (a crude drug amount), wherein contains THH crude drug amount 86.97g/kg.Be equivalent to 217 times of clinical consumption.
(4) maximum tolerated dose of no THH compound mixture: same, recording the peroral administration maximum tolerated dose of no THH compound mixture is 380.95g/kg (crude drug amount).Be equivalent to 209 times of clinical consumption.
The alcohol extract LD that experiment showed, THH in the past
50For 35.9g/kg (crude drug amount), with the LD of alcohol extract
50Similar for 35.57g/kg (crude drug amount) result, draw the LD of THH water extract through experiment
50Be 78.02g/kg (crude drug amount), 95% the credible 67.51g/kg～90.17g/kg that is limited to,, compare with alcohol extract (95% the credible 30.52g/kg of being limited to～41.46g/kg), do not intersect during credible, the acute toxicity of visible THH water extract is littler than alcohol extract.And do not measure LD in the compound mixture (medicine of the present invention)
50, the compound mixture maximum tolerated dose is 439.20g/kg (a crude drug amount), wherein contains THH crude drug amount 86.97g/kg, greater than the LD of THH water extract
50, the acute toxicity of visible compound mixture is less than the THH water extract, more less than alcohol extract, illustrates that compound mixture has littler acute toxicity, bigger safety.
The experimentation of the anti-mice photoallergy of compound recipe Tripterygium hypoglaucum (medicine of the present invention)
(1) experiment grouping: 1. 70 Balb/c pure lines female mices are divided into～7. organize four groups of drug study groups (1. organizing～4. organize) at random:
1. compound recipe Tripterygium hypoglaucum mixture group: nine flavor medicines such as Tripterygium hypoglaucum 20g, Radix Scutellariae, Radix Glycyrrhizae are 101g altogether
2. Tripterygium hypoglaucum list agent group (water extraction) Tripterygium hypoglaucum 20g
3. there is not Tripterygium hypoglaucum compound mixture group: the mixture (being eight flavor medicines such as Radix Scutellariae, Radix Glycyrrhizae 81g altogether) of promptly removing Tripterygium hypoglaucum
4. Tripterygium hypoglaucum list agent group (alcohol extraction): Tripterygium hypoglaucum extractum 20g
The agent of Tripterygium hypoglaucum list is clinical common dose in the above medicine, each is organized equal Tripterygium hypoglaucum dosage in the equal volume, all the other each medicines are state-promulgated pharmacopoeia human body consumption, and concentration is all calibrated, when giving mice 0.2ml/10g, be equivalent to 10 times of human body kg body weight consumption by above-mentioned concentration.
Two groups of positive controls (5. organizing～6. organize):
5. organize: (dosage is 24mgkg to hydrocortisone
-1D
-1, give mice with normal saline 0.2ml/10g, be equivalent to 10 times of human body kg body weight consumption)
6. organize: (dosage is 80mgkg to hydroxychloroquine
-1D
-1, be that 0.2ml/10g gives mice with physiological saline solution, be equivalent to 10 times of human body kg body weight consumption)
One group of negative control: 7. organize: normal saline
(2) administration
Set up the PACD animal model with 70 of female mices of Balb/c pure lines and do pharmacodynamics, pharmacological experiment, be divided into 7 groups at random by above-mentioned, every group of 10 mices, the PACD animal model is pressed preceding method substantially and is set up, difference is to induce the back to be coated with 0.1%CPZ-ethanol liquid on the 8th day outside left ear, auris dextra is not coated with, and then shines UVA.From photosensitive preceding 4 days beginning gastric infusions, each 0.2ml/10g, once a day, each according to UVA gave in preceding 30 minutes the same day dose, be administered to and induce the 8th day (promptly the exciting the same day) in back.
(3) influence of each experimental group and the anti-photoallergy of matched group
1. to the influence of mouse ear thickness and weight difference see Table 4, Fig. 2 and Fig. 3.Each administration group statistical significance (P＜0.01) of having compared with the normal saline group is the strongest with the effect of compound recipe Tripterygium hypoglaucum mixture group in each group of Chinese medicine.The mixture of compound recipe Tripterygium hypoglaucum mixture and the agent of Tripterygium hypoglaucum list and no Tripterygium hypoglaucum relatively has relatively not statistically significant (P＞0.05) of statistical significance (P＜0.05) and hydrocortisone and hydroxychloroquine
Table 4 is respectively organized the influence (X of medicine to mouse ear thickness and weight difference
± s, n=10)
Group n S1 S2 S3
Normal saline 10 7.80 ± 2.39 6.40 ± 1.83 1.24 ± 0.21
Hydrocortisone 10 2.80 ± 1.39
*2.00 ± 1.33
*0.42 ± 0.18
*
Hydroxychloroquine 10 4.00 ± 1.63
*2.80 ± 1.39
*0.57 ± 0.19
*
Compound recipe Tripterygium hypoglaucum 10 3.80 ± 1.47
*2.40 ± 0.84
*0.51 ± 0.16
*
Water is carried Tripterygium hypoglaucum 10 5.60 ± 1.57
The * Δ4.00 ± 1.33
* Δ Δ0.71 ± 0.18
The * Δ
No Tripterygium hypoglaucum compound recipe 10 6.00 ± 1.63
* Δ Δ4.40 ± 1.26
* Δ Δ0.76 ± 0.20
* Δ Δ
Alcohol extraction Tripterygium hypoglaucum 10 5.40 ± 1.35
The * Δ3.60 ± 1.27
* Δ0.70 ± 0.23
The * Δ
Annotate: s1 induces preceding and excites a 48h left side, back ear thickness difference, the 10 μ m of unit.S2 excites the 48h left and right sides, back ear thickness difference, the 10 μ m of unit.S3 excites the 48h left and right sides, back ear weight difference, the mg of unit.Compare with negative control (normal saline group): * P＜0.05, * * P＜0.01; Compare with the compound recipe Tripterygium hypoglaucum: Δ P＜0.05, Δ Δ P＜0.01.
2. to exciting the influence of back mice mononuclear cell infiltration, see Table 5 and Fig. 3, each administration group is compared with the normal saline group all has statistical significance (P＜0.01), and compound recipe Tripterygium hypoglaucum effect is best in the experimental group, compare with other three groups, significant difference (P＜0.01) is all arranged.
Each group of table 5 excites relatively (X of the single nucleus difference of back mice mice left and right sides ear
± s, n=10) (individual/mm
2)
The single nucleus P of group n value
Normal saline 10 954.10 ± 128.27
Hydrocortisone 10 97.10 ± 39.77＜0.01
*
Hydroxychloroquine 10 254.80 ± 66.31＜0.01
*
Compound recipe Tripterygium hypoglaucum 10 184.90 ± 67.95＜0.01
*
Water is carried Tripterygium hypoglaucum 10 396.60 ± 107.67＜0.01
* Δ
No Tripterygium hypoglaucum compound recipe 10 447.50 ± 131.25＜0.01
* Δ
Alcohol extraction Tripterygium hypoglaucum 10 363.50 ± 102.62＜0.01
* Δ
Annotate:
*Show with negative control (normal saline group) and compare; Δ shows with the compound recipe Tripterygium hypoglaucum to be compared
3. to exciting the influence of back mice ICAM-1 of ear and serum I FN-γ, see Table 6, each group is compared with normal saline, and serum I FN-γZhi reduces, and the ICAM-1 expression decreased has statistical significance, and the single agent of compound recipe THH and water extraction THH relatively has statistical significance.
Table 6 excites the influence (X of back mice ICAM-1 of ear and serum I FN-γ
± s, n=10)
Group n ICAM-1 serum I FN-γ
Normal saline 10 4.40 ± 0.69 937.90 ± 76.36
Hydrocortisone 10 2.10 ± 0.73
*810.00 ± 20.61
*
Compound recipe Tripterygium hypoglaucum 10 2.80 ± 0.73
*822.60 ± 25.62
*
Water is carried Tripterygium hypoglaucum 10 3.50 ± 0.70
The * Δ856.50 ± 17.57
*
Annotate: each group * that compares with normal saline is (P＜0.05, * * is P＜0.01); Compound recipe Tripterygium hypoglaucum and water are carried the Tripterygium hypoglaucum Δ of comparing and are (P＜0.01) for (P＜0.05) Δ Δ.
(4) discuss
Experimental studies results through the anti-mice photoallergy of compound recipe Tripterygium hypoglaucum draws: the thickness difference of cubic Chinese medicine before and after left ear excites, excite the thickness difference of the left and right sides, back ear and the weight difference of piece of tissue, a plurality of observation index such as the single nucleus of local infiltration all have remarkable result, wherein compound recipe Tripterygium hypoglaucum mixture group all obviously is better than Tripterygium hypoglaucum list agent group (water extraction and alcohol extraction) and does not have the mixture group of Tripterygium hypoglaucum on four objective indicators or on histo pathological change, and has antiallergic, immunosuppressant hydrocortisone and have antiinflammatory, anti-photosensitive hydroxychloroquine positive controls is compared there was no significant difference.Synergism such as Radix Scutellariae in the compound recipe Tripterygium hypoglaucum mixture is described, has strengthened antiinflammatory, the immunoregulation effect of Tripterygium hypoglaucum really, thereby made it to have the effect of stronger anti-photoallergy.And the anti-photoallergy of compound recipe Tripterygium hypoglaucum one of the mechanism of action be to suppress the secretion of IFN-γ, thereby the expression of downward modulation ICAM-1, suppress the generation of the lymphocytic activation of T and reduction T lymphocyte chemotactic and inflammatory factor, reduce the infiltration of local single nucleus and play antiinflammatory, immunoregulatory effect, and stronger than the effect of Tripterygium hypoglaucum list agent.
Show from above-mentioned clinical research:
(1) the multiple dermatosis relevant with immunity of compound recipe THH (Tripterygium hypoglaucum) treatment has curative effect preferably.
(2) compound recipe THH mixture acute toxicity is less than THH water extract and alcohol extract.
(3) compound recipe THH experimental group has significant anti-photoallergy effect, and its effect is than the water extract and the alcohol extract of the single agent of THH and not have the compound mixture of compound recipe THH strong.
(4) mechanism of action of the anti-PACD of compound recipe THH partly is the expression that suppresses the secretion of interferon-(IFN-γ) and suppress epidermis, intradermal ICAM-1, thereby reduces the infiltration of local single nucleus, alleviates allergy.
(5) compound recipe THH has better clinical application value than the single agent of THH.
Description of drawings
Fig. 1 is that medicine of the present invention influences lab diagram to the thick difference of mouse ear;
Fig. 2 influences lab diagram for medicine of the present invention excites the back to mice left and right sides ear weight difference;
Fig. 3 respectively organizes mice left and right sides ear lymphocyte count difference lab diagram after medicine of the present invention excites.
The specific embodiment
Embodiment 1:
Take by weighing raw material (kilogram) by following proportioning:
Tripterygium hypoglaucum 15 Herba Artemisiae Annuaes 6 Radix Scutellariaes 3 Cortex Dictamnis 4.5
Radix Salviae Miltiorrhizae 9 Rhizoma Corydalis 3 Rhizoma Pinelliae Preparata 3 Semen Cuscutae 6 Radix Glycyrrhizaes 1.5
Production method is as follows:
Above-mentioned each component is made medicine production method of the present invention is:
(1) after being mixed in proportion, above-mentioned medicine raw material is crushed to coarse granule;
(2) soaked 10～12 hours;
(3) in the multi-functional extractor 60 ℃, add 7 times of water gagings, slow fire boiling about 30 minutes, extract secondary;
(4) get volatile oil and filtrate, merge secondary filtrate;
(5) filtrate being concentrated into contained crude drug amount 3.37g/ml (relative density 1.2);
(6) add volatile oil, antiseptic, correctives (antiseptic and correctives are pressed the Chinese medicine conventional method and added);
(7) quality control, packing, sterilization, dermopathic mixture can obtain medical treatment.
Embodiment 2:
Take by weighing raw material (kilogram) by following proportioning:
Tripterygium hypoglaucum 20 Herba Artemisiae Annuaes 9 Radix Scutellariaes 6 Cortex Dictamnis 6
Radix Salviae Miltiorrhizae 12 Rhizoma Corydalis 6 Rhizoma Pinelliae Preparata 6 Semen Cuscutae 9 Radix Glycyrrhizaes 6
Production method is as follows:
(1) identical to (5) step with embodiment 1;
(6) concentrate the back spray drying, get extract powder;
(7) add volatile oil, sucrose dextrin (the sucrose dextrin is pressed the Chinese medicine conventional method and added), granulate drying;
(8) granulate, total mixing, granule packing (every bag contains total crude drug amount 26.67 grams), packing, quality examination gets the finished particle agent.
Embodiment 3:
Take by weighing raw material (kilogram) by following proportioning:
Tripterygium hypoglaucum 30 Herba Artemisiae Annuaes 12 Radix Scutellariaes 9 Cortex Dictamnis 9
Radix Salviae Miltiorrhizae 15 Rhizoma Corydalis 9 Rhizoma Pinelliae Preparata 9 Semen Cuscutae 12 Radix Glycyrrhizaes 9
Production method is as follows:
(1) identical to (5) step with embodiment 1;
(6) concentrate the back spray drying, get extract powder;
(7) add volatile oil, sucrose dextrin (the sucrose dextrin is pressed the Chinese medicine conventional method and added), granulate drying;
(8) granulate, total mixing are divided encapsulated (every capsules contains total crude drug amount 6.67 grams), packing, and quality examination gets the finished capsule product agent.
Claims (5)
1, the dermopathic medicine of a kind of treatment is characterized in that it is the medicament of being made by the following weight proportion raw material
Tripterygium hypoglaucum 15～30 Herba Artemisiae Annuaes 6～12 Radix Scutellariaes 3～9 Cortex Dictamnis 4.5～9
Radix Salviae Miltiorrhizae 9～15 Rhizoma Corydalis 3～9 Rhizoma Pinelliae Preparata 3～9 Semen Cuscutae 6～12 Radix Glycyrrhizaes 1.5～9
2, according to the dermopathic medicine of treatment of claim 1, wherein the weight proportion of each raw material is
Tripterygium hypoglaucum 12～25 Herba Artemisiae Annuaes 8～10 Radix Scutellariaes 5～7 Cortex Dictamnis 5.5～7
Radix Salviae Miltiorrhizae 10～12 Rhizoma Corydalis 5～7 Rhizoma Pinelliae Preparata 5～7 Semen Cuscutae 8～10 Radix Glycyrrhizaes 3.5～7
3, according to claim 1,2 the dermopathic medicine of treatment, it is characterized in that described medicament is a said dosage form on any pharmaceutics.
4, according to the dermopathic medicine of treatment of claim 3, it is characterized in that described medicament is mixture, granule and capsule.
5, the preparation method of the dermopathic medicine of treatment of claim 4 is characterized in that producing according to the following steps:
The preparation of A, mixture
(1) after being mixed in proportion, above-mentioned medicine raw material is crushed to coarse granule;
(2) soaked 10～12 hours;
(3) in the multi-functional extractor 60 ℃, add 6～8 times of water gagings, slow fire boiling about 30 minutes, extract secondary;
(4) get volatile oil and filtrate, merge secondary filtrate;
(5) filtrate is concentrated;
(6) add volatile oil, antiseptic, correctives;
(7) quality control, packing, sterilization, dermopathic mixture can obtain medical treatment.
The preparation of B, granule or capsule
(1) identical to (5) step with above-mentioned mixture;
(6) concentrate the back spray drying, get extract powder;
(7), granulate drying with the sucrose dextrin;
(8) granulate, total mixing, the granule packing, packing, quality examination gets finished particle agent or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135362 CN1243560C (en) | 2003-07-05 | 2003-07-05 | Medicine for treating dermatosis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03135362 CN1243560C (en) | 2003-07-05 | 2003-07-05 | Medicine for treating dermatosis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513515A true CN1513515A (en) | 2004-07-21 |
| CN1243560C CN1243560C (en) | 2006-03-01 |
Family
ID=34240016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03135362 Expired - Fee Related CN1243560C (en) | 2003-07-05 | 2003-07-05 | Medicine for treating dermatosis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1243560C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116265027A (en) * | 2021-12-16 | 2023-06-20 | 四川大学华西医院 | A Chinese medicinal compound preparation containing Tripterygium for treating inflammatory dermatoses |
| WO2024012387A1 (en) * | 2022-07-15 | 2024-01-18 | 上海家化联合股份有限公司 | Composition comprising artemisia annua extract and water-soluble component, and use thereof |
-
2003
- 2003-07-05 CN CN 03135362 patent/CN1243560C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116265027A (en) * | 2021-12-16 | 2023-06-20 | 四川大学华西医院 | A Chinese medicinal compound preparation containing Tripterygium for treating inflammatory dermatoses |
| WO2024012387A1 (en) * | 2022-07-15 | 2024-01-18 | 上海家化联合股份有限公司 | Composition comprising artemisia annua extract and water-soluble component, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1243560C (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857352A (en) | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases | |
| CN1297291C (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1742949A (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN1857654A (en) | Trachaitis treating preparation and its preparing process | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1775279A (en) | Gynaecologic formulation and new preparing method | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1243560C (en) | Medicine for treating dermatosis and its preparation method | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1509741A (en) | Chinese medicinal preparation for preventing herpes virus and preparing method thereof | |
| CN1246016C (en) | Compound formulation of traditional Chinese medicine for climacteric syndrome and preparation method | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1166379C (en) | Medicine for treating kidney disease and method for preparing same | |
| CN1660259A (en) | Chinese traditional medicine for treating imitable bowel syndrome and preparation method | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1709381A (en) | Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method | |
| CN1709329A (en) | Composition for treating female algomenorrhea and its preparing method | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN1289139C (en) | Medicine for treating colitis and its preparing method | |
| CN1225277C (en) | Chinese medicinal composition for treating epilepsy disease and its preparation method | |
| CN1579441A (en) | Cough-relieving medicine and its preparation method | |
| CN100337679C (en) | Chinese traditional medicine capable of invigorating yang and strengthening qi and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060301 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |